UK Biobank (core renewal)
Lead Research Organisation:
UK Biobank
Department Name: UNLISTED
Abstract
UK Biobank is supported by The Wellcome Trust, The National Institute of Health Research, The Medical Research Council, The British Heart Foundation and Cancer Research UK. The figures presented on this record represent the Medical Research Council funding contribution only with some additional UKRI Infrastructure funds in addition.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
Technical Summary
The UK Biobank resource has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. There are now sufficient numbers of incident cases of the commoner conditions to support extensive and powerful research into their determinants.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
Organisations
People |
ORCID iD |
Rory Collins (Principal Investigator) |
Publications
Watson C
(2022)
003 Neuroanatomical signatures of genetic risk for Alzheimer's disease in healthy adults
in Journal of Neurology, Neurosurgery & Psychiatry
Jacobs B
(2022)
026 Gene-environment interactions in multiple sclerosis: a UK Biobank study
in Journal of Neurology, Neurosurgery & Psychiatry
Winer J
(2022)
0278 Isolated REM sleep behavior disorder is associated with 24-hour rhythm disruption
in Sleep
Binks S
(2022)
036 A GWAS of LGI1-antibody encephalitis
in Journal of Neurology, Neurosurgery & Psychiatry
Paris A
(2022)
043 Depression is associated with increased dementia risk and reduced grey matter in a fronto-insular-cerebellar network
in Journal of Neurology, Neurosurgery & Psychiatry
Freeman J
(2022)
0574 Sleep Duration and Sleep Quality in Association with Risk of Prostate Cancer in the UK Biobank
in Sleep
Kiesow H
(2020)
10,000 social brains: Sex differentiation in human brain anatomy
in Science Advances
Jacobs B
(2022)
121 The ADAMS project: protocol and baseline results
in Journal of Neurology, Neurosurgery & Psychiatry
Politis M
(2023)
1310 FRAILTY, LONELINESS AND SOCIAL ISOLATION IN THE UK BIOBANK COHORT
in Age and Ageing
Kuri A
(2022)
134 Predictors of serum vitamin D level in multiple sclerosis
in Journal of Neurology, Neurosurgery & Psychiatry
Abdellaoui A
(2023)
15 years of GWAS discovery: Realizing the promise.
in American journal of human genetics
McElheron M
(2022)
177 GENOME-WIDE ASSOCIATION ANALYSIS OF THE FRAILTY PHENOTYPE IN UK BIOBANK HIGHLIGHTS CARDIOMETABOLIC AND AUTOIMMUNE SIGNATURES IN AGEING
in Age and Ageing
Sønderby IE
(2021)
1q21.1 distal copy number variants are associated with cerebral and cognitive alterations in humans.
in Translational psychiatry
Taylor T
(2022)
211 The prevalence and characteristics of multiple sclerosis-associated uveitis in UK biobank
in Journal of Neurology, Neurosurgery & Psychiatry
Ashokumar M
(2022)
261 Hearing impairment after subarachnoid haemorrhage
in Journal of Neurology, Neurosurgery & Psychiatry
Zheng Q
(2018)
3-D Consistent and Robust Segmentation of Cardiac Images by Deep Learning With Spatial Propagation.
in IEEE transactions on medical imaging
Fairfield C
(2022)
529 Gallstone Disease and the Risk of Cardiovascular Disease - a Mendelian Randomisation Study
in British Journal of Surgery
Hurst C
(2022)
684 LONG-TERM CONDITIONS, MULTIMORBIDITY, LIFESTYLE FACTORS AND GRIP STRENGTH CHANGE OVER 9 YEARS IN 44,315 UK BIOBANK PARTICIPANTS
in Age and Ageing
Guo X
(2022)
927 MENDELIAN RANDOMIZATION ANALYSIS SHOWS A CAUSAL EFFECT OF NOISE EXPOSURE ON ALZHEIMER'S DISEASE RISK
in Age and Ageing
??? ?
(2022)
??????????? Smoking and COVID-19
in ????????
Chan M
(2021)
A Biomarker-based Biological Age in UK Biobank: Composition and Prediction of Mortality and Hospital Admissions
in The Journals of Gerontology: Series A
Christakoudi S
(2021)
A Body Shape Index (ABSI), hip index, and risk of cancer in the UK Biobank cohort.
in Cancer medicine
Feng L
(2020)
A close relationship between Helicobacter pylori infection and the serum level of CD47 in adults.
in Scandinavian journal of gastroenterology
Hill W
(2018)
A combined analysis of genetically correlated traits identifies 187 loci and a role for neurogenesis and myelination in intelligence
in Molecular Psychiatry
Dite GS
(2023)
A combined clinical and genetic model for predicting risk of ovarian cancer.
in European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
Liu W
(2021)
A combined genome-wide association and molecular study of age-related hearing loss in H. sapiens.
in BMC medicine
Khawaja AP
(2018)
A Common Glaucoma-risk Variant of SIX6 Alters Retinal Nerve Fiber Layer and Optic Disc Measures in a European Population: The EPIC-Norfolk Eye Study.
in Journal of glaucoma
Nerland S
(2022)
A comparison of intracranial volume estimation methods and their cross-sectional and longitudinal associations with age.
in Human brain mapping
Al Ozairi E
(2022)
A comparison of physical activity, muscle strength, and sleep between people with type 2 diabetes in Kuwait and the UK: A cross-sectional study
in Frontiers in Endocrinology
Dehghani N
(2021)
A comprehensive analysis of copy number variation in a Turkish dementia cohort.
in Human genomics
Shao Z
(2022)
A comprehensive comparison of multilocus association methods with summary statistics in genome-wide association studies
in BMC Bioinformatics
Wang C
(2023)
A comprehensive investigation of statistical and machine learning approaches for predicting complex human diseases on genomic variants.
in Briefings in bioinformatics
Leppert B
(2020)
A cross-disorder PRS-pheWAS of 5 major psychiatric disorders in UK Biobank.
in PLoS genetics
Sakaue S
(2021)
A cross-population atlas of genetic associations for 220 human phenotypes.
in Nature genetics
Yildirim AM
(2022)
A cross-sectional study of male balding patterns in people of color.
in Journal of the American Academy of Dermatology
Tanguay-Sabourin C
(2022)
A Data-Driven Biopsychosocial Framework Determining the Spreading of Chronic Pain
Azevedo T
(2022)
A deep graph neural network architecture for modelling spatio-temporal dynamics in resting-state functional MRI data.
in Medical image analysis
Description | Impact of clinically silent atrial fibrillation on cerebrovascular disease and cognitive decline in the UK Biobank Imaging Cohort |
Amount | £2,474,260 (GBP) |
Funding ID | RG/18/6/33576 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2019 |
End | 06/2024 |
Description | UK Biobank - The Repeat Imaging Project |
Amount | £2,500,000 (GBP) |
Funding ID | R39738/CN039 |
Organisation | MRC Dementias Platform UK |
Sector | Academic/University |
Country | United Kingdom |
Start | 04/2019 |
End | 01/2023 |
Description | UK Biobank - Whole genome sequencing of 50,000 UKB participants |
Amount | £30,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2020 |
Description | UK Biobank- Expansion of the UKB imaging to a 4th centre and repeat imaging assessment of 10,000 participants |
Amount | £8,500,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 12/2022 |
Description | UK Biobank Scientific Conference |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | The UK Biobank Scientific Symposium included presentations about the successes and future plans of the UK Biobank. It took place on 21 June 2018 in London |
Year(s) Of Engagement Activity | 2018 |
Description | UK Biobank participant imaging event |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UK Biobank for participants of the imaging work |
Year(s) Of Engagement Activity | 2021 |
Description | UKBiobank participant events - 2014 - 2019 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UKB Biobank participants regularly attend events aimed at informing them about the work being undertaken with their data. Usually, the events last a few hours and include an overview from the chief scientist and two talks from scientists that have used UKB data. From 2014 - 2020 over 4,000 participants have taken part in events in Edinburgh (4), Manchester (4), Nottingham, Leeds, Cardiff (2), Newcastle (5), Glasgow (2), Bristol (2) and Reading(4). They are often over-subscribed and participants leave these events wishing to seek more information and support he programme in new ways (EG in imaging, genome sequencing) |
Year(s) Of Engagement Activity | 2014,2015,2016,2017,2018,2019 |
URL | http://www.ukbiobank.ac.uk |